Prognostic Impact of Sarcopenia in Patients with Advanced Prostate Carcinoma: A Systematic Review
Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death from cancer. The possibility of sarcopenia being a prognostic factor in advanced PCa patients has recently become a subject of interest. The aim of the present study was to evaluate the prognostic valu...
Uloženo v:
| Vydáno v: | Journal of clinical medicine Ročník 12; číslo 1; s. 57 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
MDPI AG
21.12.2022
MDPI |
| Témata: | |
| ISSN: | 2077-0383, 2077-0383 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death from cancer. The possibility of sarcopenia being a prognostic factor in advanced PCa patients has recently become a subject of interest. The aim of the present study was to evaluate the prognostic value of sarcopenia in advanced prostate carcinoma. A systematic review was conducted in Medline, EMBASE, and Web of Science (March, 2021). The quality of studies was assessed using the Quality in Prognosis Studies tool. Meta-analyses for overall, cancer-specific, and progression-free survival were performed. Nine studies (n = 1659) were included. Sarcopenia was borderline associated with a shorter overall survival (HR = 1.20, 95% CI: 1.01, 1.44, P = 0.04, I2 = 43%) but was significantly associated with progression-free survival (HR = 1.61, 95% CI: 1.26, 2.06, P < 0.01; k = 3; n = 588). Available evidence supports sarcopenia as an important prognostic factor of progression-free survival in patients with advanced PCa. However, sarcopenia has a weak association with a shorter overall survival. The evidence on the role of sarcopenia in prostate-cancer-specific survival is insufficient and supports the need for further research. Patient summary: The literature was reviewed to determine whether the loss of muscle mass (sarcopenia) affects the survival in patients with advanced PCa. Patients with advanced PCa and sarcopenia were found to have a shorter progression-free survival (the length of time during and after treatment of a cancer that the patient lives with the disease but it does not get worse), but sarcopenia did not have much influence on the overall survival and cancer-specific survival (the length of time from either the date of diagnosis or the start of treatment to the date of death due to the cancer). |
|---|---|
| AbstractList | Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death from cancer. The possibility of sarcopenia being a prognostic factor in advanced PCa patients has recently become a subject of interest. The aim of the present study was to evaluate the prognostic value of sarcopenia in advanced prostate carcinoma. A systematic review was conducted in Medline, EMBASE, and Web of Science (March, 2021). The quality of studies was assessed using the Quality in Prognosis Studies tool. Meta-analyses for overall, cancer-specific, and progression-free survival were performed. Nine studies (n = 1659) were included. Sarcopenia was borderline associated with a shorter overall survival (HR = 1.20, 95% CI: 1.01, 1.44, P = 0.04, I2 = 43%) but was significantly associated with progression-free survival (HR = 1.61, 95% CI: 1.26, 2.06, P < 0.01; k = 3; n = 588). Available evidence supports sarcopenia as an important prognostic factor of progression-free survival in patients with advanced PCa. However, sarcopenia has a weak association with a shorter overall survival. The evidence on the role of sarcopenia in prostate-cancer-specific survival is insufficient and supports the need for further research. Patient summary: The literature was reviewed to determine whether the loss of muscle mass (sarcopenia) affects the survival in patients with advanced PCa. Patients with advanced PCa and sarcopenia were found to have a shorter progression-free survival (the length of time during and after treatment of a cancer that the patient lives with the disease but it does not get worse), but sarcopenia did not have much influence on the overall survival and cancer-specific survival (the length of time from either the date of diagnosis or the start of treatment to the date of death due to the cancer).Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death from cancer. The possibility of sarcopenia being a prognostic factor in advanced PCa patients has recently become a subject of interest. The aim of the present study was to evaluate the prognostic value of sarcopenia in advanced prostate carcinoma. A systematic review was conducted in Medline, EMBASE, and Web of Science (March, 2021). The quality of studies was assessed using the Quality in Prognosis Studies tool. Meta-analyses for overall, cancer-specific, and progression-free survival were performed. Nine studies (n = 1659) were included. Sarcopenia was borderline associated with a shorter overall survival (HR = 1.20, 95% CI: 1.01, 1.44, P = 0.04, I2 = 43%) but was significantly associated with progression-free survival (HR = 1.61, 95% CI: 1.26, 2.06, P < 0.01; k = 3; n = 588). Available evidence supports sarcopenia as an important prognostic factor of progression-free survival in patients with advanced PCa. However, sarcopenia has a weak association with a shorter overall survival. The evidence on the role of sarcopenia in prostate-cancer-specific survival is insufficient and supports the need for further research. Patient summary: The literature was reviewed to determine whether the loss of muscle mass (sarcopenia) affects the survival in patients with advanced PCa. Patients with advanced PCa and sarcopenia were found to have a shorter progression-free survival (the length of time during and after treatment of a cancer that the patient lives with the disease but it does not get worse), but sarcopenia did not have much influence on the overall survival and cancer-specific survival (the length of time from either the date of diagnosis or the start of treatment to the date of death due to the cancer). Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death from cancer. The possibility of sarcopenia being a prognostic factor in advanced PCa patients has recently become a subject of interest. The aim of the present study was to evaluate the prognostic value of sarcopenia in advanced prostate carcinoma. A systematic review was conducted in Medline, EMBASE, and Web of Science (March, 2021). The quality of studies was assessed using the Quality in Prognosis Studies tool. Meta-analyses for overall, cancer-specific, and progression-free survival were performed. Nine studies (n = 1659) were included. Sarcopenia was borderline associated with a shorter overall survival (HR = 1.20, 95% CI: 1.01, 1.44, P = 0.04, I2 = 43%) but was significantly associated with progression-free survival (HR = 1.61, 95% CI: 1.26, 2.06, P < 0.01; k = 3; n = 588). Available evidence supports sarcopenia as an important prognostic factor of progression-free survival in patients with advanced PCa. However, sarcopenia has a weak association with a shorter overall survival. The evidence on the role of sarcopenia in prostate-cancer-specific survival is insufficient and supports the need for further research. Patient summary: The literature was reviewed to determine whether the loss of muscle mass (sarcopenia) affects the survival in patients with advanced PCa. Patients with advanced PCa and sarcopenia were found to have a shorter progression-free survival (the length of time during and after treatment of a cancer that the patient lives with the disease but it does not get worse), but sarcopenia did not have much influence on the overall survival and cancer-specific survival (the length of time from either the date of diagnosis or the start of treatment to the date of death due to the cancer). |
| Author | del Pino-Sedeño, Tasmania Trujillo-Martín, María M. de Armas-Castellano, Aythami Ramírez Backhaus, Miguel Ferrer, Juan Francisco Loro de Pablos-Velasco, Pedro de Pablos-Rodríguez, Pedro Infante-Ventura, Diego Rueda-Domínguez, Antonio |
| AuthorAffiliation | 10 Research Network on Health Services in Chronic Diseases (REDISSEC), Carlos III Health Institute, 28029 Madrid, Spain 7 Department of Endocrinology and Nutrition, University Hospital of Gran Canaria Doctor Negrín, 35012 Las Palmas de Gran Canaria, Spain 2 Doctoral School of University of Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain 8 Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain 4 Evaluation Unit of the Canary Islands Health Service (SESCS), 38109 Santa Cruz de Tenerife, Spain 5 Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), 38109 Santa Cruz de Tenerife, Spain 3 Canary Islands Health Research Institute Foundation (FIISC), 38320 Santa Cruz de Tenerife, Spain 1 Department of Urology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain 6 Department of Clinical Sciences, University of Las Palmas de Gran Canaria (ULP |
| AuthorAffiliation_xml | – name: 7 Department of Endocrinology and Nutrition, University Hospital of Gran Canaria Doctor Negrín, 35012 Las Palmas de Gran Canaria, Spain – name: 9 Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, 29590 Malaga, Spain – name: 4 Evaluation Unit of the Canary Islands Health Service (SESCS), 38109 Santa Cruz de Tenerife, Spain – name: 10 Research Network on Health Services in Chronic Diseases (REDISSEC), Carlos III Health Institute, 28029 Madrid, Spain – name: 6 Department of Clinical Sciences, University of Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain – name: 8 Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain – name: 2 Doctoral School of University of Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain – name: 1 Department of Urology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain – name: 3 Canary Islands Health Research Institute Foundation (FIISC), 38320 Santa Cruz de Tenerife, Spain – name: 5 Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), 38109 Santa Cruz de Tenerife, Spain |
| Author_xml | – sequence: 1 givenname: Pedro orcidid: 0000-0003-2286-9893 surname: de Pablos-Rodríguez fullname: de Pablos-Rodríguez, Pedro – sequence: 2 givenname: Tasmania surname: del Pino-Sedeño fullname: del Pino-Sedeño, Tasmania – sequence: 3 givenname: Diego orcidid: 0000-0003-4197-7849 surname: Infante-Ventura fullname: Infante-Ventura, Diego – sequence: 4 givenname: Aythami surname: de Armas-Castellano fullname: de Armas-Castellano, Aythami – sequence: 5 givenname: Miguel surname: Ramírez Backhaus fullname: Ramírez Backhaus, Miguel – sequence: 6 givenname: Juan Francisco Loro orcidid: 0000-0002-0517-8209 surname: Ferrer fullname: Ferrer, Juan Francisco Loro – sequence: 7 givenname: Pedro orcidid: 0000-0002-9190-2581 surname: de Pablos-Velasco fullname: de Pablos-Velasco, Pedro – sequence: 8 givenname: Antonio orcidid: 0000-0001-5890-0149 surname: Rueda-Domínguez fullname: Rueda-Domínguez, Antonio – sequence: 9 givenname: María M. orcidid: 0000-0003-2273-2192 surname: Trujillo-Martín fullname: Trujillo-Martín, María M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36614862$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkc1rGzEQxUVJadLEp9yDoJdAcaOvXWl7CBiTpoZAQtyexaxWm8jsSu5KtvF_H7n5wA3VRYL5zdObN5_RgQ_eInRKyTfOK3KxMD1lhBJSyA_oiBEpx4QrfrD3PkSjGBckH6UEo_ITOuRlSYUq2RGCuyE8-BCTM3jWL8EkHFo8h8GEpfUOsPP4DpKzPkW8cekRT5o1eGMbnDtjgmTxNNPOhx6-4wmeb2OyPez07u3a2c0J-thCF-3o5T5Gv39c_Zr-HN_cXs-mk5uxEaRKYyCmKBUVjaxboC0zdUVMSSpgTStqxYo6D1TmasMFB6kULSplaiFES3ndEH6MLp91l6u6t43Jjgfo9HJwPQxbHcDpfyvePeqHsNaVYrQgNAucvwgM4c_KxqR7F43tOvA2rKJmsqSVIkzu_vryDl2E1eDzeH8pqiQTVabO9h29WXlNPwNfnwGTo4yDbd8QSvRuvXpvvZmm72jjcv4u7MZx3X97ngCWi6eL |
| CitedBy_id | crossref_primary_10_3389_fnut_2024_1475977 crossref_primary_10_1007_s00595_023_02721_w crossref_primary_10_1007_s10147_024_02514_2 crossref_primary_10_1097_MEG_0000000000003006 crossref_primary_10_3389_fruro_2025_1567575 crossref_primary_10_3390_nu16050656 crossref_primary_10_1016_j_euros_2023_07_007 crossref_primary_10_29254_2077_4214_2023_2_169_201_210 crossref_primary_10_1155_proc_1468262 |
| Cites_doi | 10.1097/MOU.0000000000000885 10.1016/j.clnu.2017.07.010 10.1093/gerona/gls206 10.1200/JCO.2019.37.15_suppl.e23106 10.1016/j.chest.2019.04.115 10.1016/j.juro.2017.08.103 10.1007/s00345-018-2574-2 10.1016/j.clnesp.2016.04.001 10.1016/j.ctarc.2020.100256 10.3322/caac.21660 10.1200/JCO.2012.46.5492 10.1016/j.endinu.2020.03.014 10.1016/j.eururo.2013.03.055 10.1016/j.ejca.2015.07.042 10.1054/clnu.2002.0585 10.7326/0003-4819-158-4-201302190-00009 10.1136/bmjopen-2017-016910 10.1016/j.ejca.2015.12.030 10.1038/s41391-019-0186-6 10.1080/01635581.2020.1819348 10.1016/j.juro.2018.01.069 10.1001/jamaoncol.2019.1011 10.1093/annonc/mdx271 10.1002/mus.21621 10.1186/s41512-019-0050-0 10.1186/s12885-018-4306-9 10.1016/j.arr.2017.01.006 10.3389/fonc.2020.00558 10.1634/theoncologist.2012-0169 10.1007/s00384-018-3128-1 10.1016/j.prnil.2018.04.002 10.1097/SPC.0000000000000011 10.1200/JCO.2012.45.2722 10.1002/jcsm.12468 10.1093/jjco/hyaa045 10.1136/bmjopen-2019-030080 10.1093/ageing/afy169 10.1016/j.jclinepi.2019.12.023 10.1200/JCO.2011.38.8850 10.3390/cancers12071864 10.1158/1055-9965.EPI-15-0578 10.1136/bmj.n71 10.1016/j.urology.2004.07.019 |
| ContentType | Journal Article |
| Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.3390/jcm12010057 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2077-0383 |
| ExternalDocumentID | PMC9821501 36614862 10_3390_jcm12010057 |
| Genre | Journal Article Review |
| GroupedDBID | 53G 5VS 7X7 8FI 8FJ AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFFHD AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU CITATION DIK FYUFA HMCUK HYE IAO IHR ITC KQ8 M48 MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY RPM UKHRP ALIPV NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c409t-a0c56814d7bfa1f2cb90c609a2df4b825b2076d7bd343a7881598cb444f13bd03 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 10 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000909337000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2077-0383 |
| IngestDate | Tue Nov 04 02:06:43 EST 2025 Sun Nov 09 12:19:28 EST 2025 Tue Oct 07 07:12:24 EDT 2025 Mon Jul 21 06:00:00 EDT 2025 Sat Nov 29 07:10:59 EST 2025 Tue Nov 18 22:43:43 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | meta-analysis systematic review prognosis prostatic neoplasms survival sarcopenia |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c409t-a0c56814d7bfa1f2cb90c609a2df4b825b2076d7bd343a7881598cb444f13bd03 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-2286-9893 0000-0003-2273-2192 0000-0003-4197-7849 0000-0001-5890-0149 0000-0002-9190-2581 0000-0002-0517-8209 |
| OpenAccessLink | https://www.proquest.com/docview/2761187249?pq-origsite=%requestingapplication% |
| PMID | 36614862 |
| PQID | 2761187249 |
| PQPubID | 5046890 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9821501 proquest_miscellaneous_2761980270 proquest_journals_2761187249 pubmed_primary_36614862 crossref_primary_10_3390_jcm12010057 crossref_citationtrail_10_3390_jcm12010057 |
| PublicationCentury | 2000 |
| PublicationDate | 20221221 |
| PublicationDateYYYYMMDD | 2022-12-21 |
| PublicationDate_xml | – month: 12 year: 2022 text: 20221221 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Journal of clinical medicine |
| PublicationTitleAlternate | J Clin Med |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Pinart (ref_11) 2020; 38 Rosado (ref_23) 2021; 68 Hayden (ref_14) 2013; 158 Meyer (ref_27) 2022; 40 Bahat (ref_5) 2019; 48 Ubachs (ref_7) 2019; 10 Fischer (ref_19) 2020; 25 Inglis (ref_41) 2019; 37 Pamoukdjian (ref_29) 2018; 37 Bozzetti (ref_47) 2017; 28 Niraula (ref_36) 2013; 31 Sun (ref_10) 2018; 33 ref_16 Kondrup (ref_34) 2002; 21 Inglis (ref_42) 2021; 73 Hanson (ref_40) 2013; 68 Jahrreiss (ref_28) 2021; 31 Yang (ref_9) 2019; 156 Parsons (ref_30) 2012; 17 ref_22 Moons (ref_12) 2018; 10 Antoun (ref_18) 2015; 51 Santos (ref_35) 2014; 66 Andrea (ref_26) 2020; 23 Higano (ref_38) 2004; 64 Torre (ref_2) 2016; 25 Smith (ref_6) 2012; 30 Fairman (ref_44) 2019; 9 Ohtaka (ref_24) 2019; 7 Zhang (ref_8) 2020; 20 Cushen (ref_48) 2016; 13 Lee (ref_21) 2018; 200 Attard (ref_49) 2019; 5 Wilson (ref_4) 2017; 36 Kiwata (ref_43) 2017; 7 Antoun (ref_33) 2013; 7 Yamamoto (ref_45) 2010; 41 Ikeda (ref_20) 2020; 50 ref_39 ref_37 Pak (ref_25) 2020; 10 Liu (ref_46) 2009; 2009 Tombal (ref_50) 2018; 199 Foroutan (ref_17) 2020; 121 Page (ref_13) 2021; 372 Sung (ref_1) 2021; 71 Martin (ref_31) 2013; 31 ref_3 Shachar (ref_32) 2016; 57 Grooten (ref_15) 2019; 3 |
| References_xml | – volume: 31 start-page: 315 year: 2021 ident: ref_28 article-title: The prognostic value of sarcopenia in patients with prostate cancer: A systematic review publication-title: Curr. Opin. Urol. doi: 10.1097/MOU.0000000000000885 – volume: 37 start-page: 1101 year: 2018 ident: ref_29 article-title: Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review publication-title: Clin. Nutr. doi: 10.1016/j.clnu.2017.07.010 – volume: 68 start-page: 490 year: 2013 ident: ref_40 article-title: Strength Training Induces Muscle Hypertrophy and Functional Gains in Black Prostate Cancer Patients Despite Androgen Deprivation Therapy publication-title: Journals Gerontol. Ser. A doi: 10.1093/gerona/gls206 – volume: 37 start-page: e23106 year: 2019 ident: ref_41 article-title: Impact of high-dose vitamin d supplementation on short physical performance battery and bioelectrical impedance analysis in older patients with prostate cancer on ADT publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2019.37.15_suppl.e23106 – ident: ref_16 – volume: 156 start-page: 101 year: 2019 ident: ref_9 article-title: Prognostic Value of Sarcopenia in Lung Cancer publication-title: Chest doi: 10.1016/j.chest.2019.04.115 – volume: 199 start-page: 459 year: 2018 ident: ref_50 article-title: Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results publication-title: J. Urol. doi: 10.1016/j.juro.2017.08.103 – volume: 38 start-page: 613 year: 2020 ident: ref_11 article-title: Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: A systematic review publication-title: World J. Urol. doi: 10.1007/s00345-018-2574-2 – volume: 2009 start-page: CD002759 year: 2009 ident: ref_46 article-title: Progressive resistance strength training for improving physical function in older adults publication-title: Cochrane Database Syst. Rev. – volume: 13 start-page: e39 year: 2016 ident: ref_48 article-title: Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel publication-title: Clin. Nutr. ESPEN doi: 10.1016/j.clnesp.2016.04.001 – volume: 25 start-page: 100256 year: 2020 ident: ref_19 article-title: Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer publication-title: Cancer Treat. Res. Commun. doi: 10.1016/j.ctarc.2020.100256 – volume: 71 start-page: 209 year: 2021 ident: ref_1 article-title: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 – volume: 31 start-page: 2029 year: 2013 ident: ref_36 article-title: Treatment of Prostate Cancer with Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.46.5492 – volume: 68 start-page: 92 year: 2021 ident: ref_23 article-title: Efecto de la densidad muscular en pacientes con cáncer de próstata metastásico tratados con terapia de privación androgénica publication-title: Endocrinol. Diabet. Nutr. doi: 10.1016/j.endinu.2020.03.014 – volume: 66 start-page: 232 year: 2014 ident: ref_35 article-title: Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group publication-title: Eur. Urol. doi: 10.1016/j.eururo.2013.03.055 – volume: 40 start-page: 103.e9 year: 2022 ident: ref_27 article-title: CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis publication-title: Urol. Oncol. Semin. Orig. Investig. – volume: 51 start-page: 2570 year: 2015 ident: ref_18 article-title: High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2015.07.042 – volume: 21 start-page: 461 year: 2002 ident: ref_34 article-title: Incidence of nutritional risk and causes of inadequate nutritional care in hospitals publication-title: Clin. Nutr. doi: 10.1054/clnu.2002.0585 – volume: 158 start-page: 280 year: 2013 ident: ref_14 article-title: Assessing Bias in Studies of Prognostic Factors publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-158-4-201302190-00009 – volume: 7 start-page: e016910 year: 2017 ident: ref_43 article-title: A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy publication-title: BMJ Open doi: 10.1136/bmjopen-2017-016910 – volume: 57 start-page: 58 year: 2016 ident: ref_32 article-title: Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2015.12.030 – volume: 23 start-page: 309 year: 2020 ident: ref_26 article-title: Assessment of body composition in the advanced stage of castration-resistant prostate cancer: Special focus on sarcopenia publication-title: Prostate Cancer Prostatic Dis. doi: 10.1038/s41391-019-0186-6 – volume: 73 start-page: 1882 year: 2021 ident: ref_42 article-title: Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT publication-title: Nutr. Cancer doi: 10.1080/01635581.2020.1819348 – volume: 200 start-page: 114 year: 2018 ident: ref_21 article-title: Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer publication-title: J. Urol. doi: 10.1016/j.juro.2018.01.069 – volume: 5 start-page: 1159 year: 2019 ident: ref_49 article-title: Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.1011 – volume: 10 start-page: ED000129 year: 2018 ident: ref_12 article-title: Implementing systematic reviews of prognosis studies in Cochrane publication-title: Cochrane Database Syst. Rev. – volume: 28 start-page: 2107 year: 2017 ident: ref_47 article-title: Forcing the vicious circle: Sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx271 – volume: 41 start-page: 819 year: 2010 ident: ref_45 article-title: Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats publication-title: Muscle Nerve doi: 10.1002/mus.21621 – ident: ref_3 – volume: 3 start-page: 1 year: 2019 ident: ref_15 article-title: Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS—Aspects of interrater agreement publication-title: Diagn. Progn. Res. doi: 10.1186/s41512-019-0050-0 – ident: ref_39 doi: 10.1186/s12885-018-4306-9 – volume: 36 start-page: 1 year: 2017 ident: ref_4 article-title: Frailty and sarcopenia: The potential role of an aged immune system publication-title: Ageing Res. Rev. doi: 10.1016/j.arr.2017.01.006 – volume: 20 start-page: 1 year: 2020 ident: ref_8 article-title: Sarcopenia as a predictor of mortality in women with breast cancer: A meta-analysis and systematic review publication-title: BMC Cancer – volume: 10 start-page: 558 year: 2020 ident: ref_25 article-title: Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer publication-title: Front. Oncol. doi: 10.3389/fonc.2020.00558 – volume: 17 start-page: 1240 year: 2012 ident: ref_30 article-title: The Relationship Between Body Composition and Response to Neoadjuvant Chemotherapy in Women with Operable Breast Cancer publication-title: Oncologist doi: 10.1634/theoncologist.2012-0169 – ident: ref_37 – volume: 33 start-page: 1419 year: 2018 ident: ref_10 article-title: Can sarcopenia be a predictor of prognosis for patients with non-metastatic colorectal cancer? A systematic review and meta-analysis publication-title: Int. J. Color. Dis. doi: 10.1007/s00384-018-3128-1 – volume: 7 start-page: 9 year: 2019 ident: ref_24 article-title: Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy publication-title: Prostate Int. doi: 10.1016/j.prnil.2018.04.002 – volume: 7 start-page: 383 year: 2013 ident: ref_33 article-title: Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer publication-title: Curr. Opin. Support. Palliat. Care doi: 10.1097/SPC.0000000000000011 – volume: 31 start-page: 1539 year: 2013 ident: ref_31 article-title: Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.45.2722 – volume: 10 start-page: 1165 year: 2019 ident: ref_7 article-title: Sarcopenia and ovarian cancer survival: A systematic review and meta-analysis publication-title: J. Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.12468 – volume: 50 start-page: 933 year: 2020 ident: ref_20 article-title: Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer publication-title: Jpn. J. Clin. Oncol. doi: 10.1093/jjco/hyaa045 – volume: 9 start-page: e030080 year: 2019 ident: ref_44 article-title: Examining the effects of creatine supplementation in augmenting adaptations to resistance training in patients with prostate cancer undergoing androgen deprivation therapy: A randomised, double-blind, placebo-controlled trial publication-title: BMJ Open doi: 10.1136/bmjopen-2019-030080 – volume: 48 start-page: 16 year: 2019 ident: ref_5 article-title: Sarcopenia: Revised European consensus on definition and diagnosis publication-title: Age Ageing doi: 10.1093/ageing/afy169 – volume: 121 start-page: 62 year: 2020 ident: ref_17 article-title: GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: Rating certainty in identification of groups of patients with different absolute risks publication-title: J. Clin. Epidemiology doi: 10.1016/j.jclinepi.2019.12.023 – volume: 30 start-page: 3271 year: 2012 ident: ref_6 article-title: Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.38.8850 – ident: ref_22 doi: 10.3390/cancers12071864 – volume: 25 start-page: 16 year: 2016 ident: ref_2 article-title: Global Cancer Incidence and Mortality Rates and Trends—An Update publication-title: Cancer Epidemiol. Biomark. Prev. doi: 10.1158/1055-9965.EPI-15-0578 – volume: 372 start-page: n71 year: 2021 ident: ref_13 article-title: The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews publication-title: BMJ doi: 10.1136/bmj.n71 – volume: 64 start-page: 1182 year: 2004 ident: ref_38 article-title: Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression publication-title: Urology doi: 10.1016/j.urology.2004.07.019 |
| SSID | ssj0000884217 |
| Score | 2.2781012 |
| SecondaryResourceType | review_article |
| Snippet | Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death from cancer. The possibility of sarcopenia being a... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 57 |
| SubjectTerms | Age Androgens Bias Cancer therapies Chemotherapy Clinical medicine Collaboration Lung cancer Medical prognosis Meta-analysis Metastasis Mortality Muscle strength Musculoskeletal system Prostate cancer Review Sarcopenia Systematic review |
| Title | Prognostic Impact of Sarcopenia in Patients with Advanced Prostate Carcinoma: A Systematic Review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36614862 https://www.proquest.com/docview/2761187249 https://www.proquest.com/docview/2761980270 https://pubmed.ncbi.nlm.nih.gov/PMC9821501 |
| Volume | 12 |
| WOSCitedRecordID | wos000909337000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2077-0383 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000884217 issn: 2077-0383 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2077-0383 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000884217 issn: 2077-0383 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central (New) customDbUrl: eissn: 2077-0383 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000884217 issn: 2077-0383 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2077-0383 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000884217 issn: 2077-0383 databaseCode: PIMPY dateStart: 20190101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RLUJceD8CpTJST0hRbce7TrigpWpFD11FFKTlFPkRq4toUna3_H5mEm_YAuLCJTnMSIk0M_Z8M_Y3AAfG1Q6zCJly4yepGnufGopHJU0QtQuTogjdsAk9m-XzeVHGgtsqHqvcrIndQu1bRzXyQ4l4W-Qa0cK7q-8pTY2i7mocobEDu8RUpkaw-_54Vn4cqiwYQwqT7v5iXob4_vCruxTUAea0IW1vRX_kl78fk9zad07u_-8fP4B7MeNk095FHsKtunkEd85iT_0xmHLZ0mk7FLPT7s4kawM7xwCgyVoLwxYNK3v21RWjsi2bxnMDrKQrI5issiOaSNS0l-Ytm7LzgRya9Z2HJ_D55PjT0Yc0Dl5IHcK9dWq4I14y5bUNRgTpbMHdhBdG-qAsYkoruZ6g1GcqM0RIPy5yZ5VSQWTW8-wpjJq2qZ8DQwzsnfO1DhZ9wBRWy9yMrVZW8OBtncCbjQ0qF1nJaTjGtwrRCRms2jJYAgeD8lVPxvF3tb2NQaoYkavqlzUSeD2IMZaoQWKaur3udYocgTpP4Flv--E7GSUyCP8S0De8YlAgnu6bkmZx0fF1FznmVVy8-PdvvYS7kq5WCJlKsQej9fK6fgW33Y_1YrXchx09190z349Oju_y9Kz88hO5CgnF |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLQIuvB-BAkYqF6SojuPdxEgIrQpVV-2uIrVI5RT8iNWtaFJ2tyD-FL-Rmc2DLSBuPXAeK3Hiz-P5PC-ATW0Li1aECLl2g1D2nQs17UcptI8K6wdK-WWziWQySY-OVLYGP9pcGAqrbHXiUlG7ytId-ZZAvh2lCbKFt2dfQuoaRd7VtoVGDYu94vs3pGzzN6N3uL4vhdh5f7i9GzZdBUKLXGYRam6p6JZ0ifE68sIaxe2AKy2clwYJkxHI7VHqYhlrqrbeV6k1UkofxcbxGJ97BdYlgj3twXo2Gmcfu1sd3LMSjfw6ETCOFd86sacReZw5HYCrR98f9uzvYZkr59zOrf_tD92Gm41FzYb1FrgDa0V5F66Nm5iBe6CzWUXRhChmo2VOKKs8O8B5UuewqWbTkmV1ddk5o2tpNmziIlhGKTFojLNt6rhUVqf6NRuyg674Nas9K_fhw6V84APolVVZPAKGHN9Z64rEG8S4ViYRqe6bRJqIe2eKAF61a57bpuo6Nf_4nCP7IoDkKwAJYLMbfFYXG_n7sI0WAHmjceb5r9UP4EUnRl1BDiBdFtV5PUalXCQ8gIc11rr3xGSoIb0NILmAwm4A1SG_KCmnx8t65CpFu5FHj_89redwffdwvJ_vjyZ7T-CGoDSSSIQi2oDeYnZePIWr9utiOp89azYVg0-XjdKfWoRi7A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VFlVceFMCBYxULkjROo53E1dCaNWyYlW6ilSQyin4EauLaFJ2tyD-Wn8dM5sHW0DceuA8VuLE34zns-cBsKNtYdGLECHXbhDKvnOhJn2UQvuosH6glF82m0gmk_T4WGVrcNHmwlBYZWsTl4baVZbOyHsC-XaUJsgWer4Ji8j2R6_PvobUQYpuWtt2GjVEDoof35G-zV-N93GtXwgxevN-723YdBgILfKaRai5pQJc0iXG68gLaxS3A660cF4aJE9GIM9HqYtlrKnyel-l1kgpfRQbx2N87jXYQJdcoo5tZOPD7GN3woP6K9Hhr5MC41jx3md7GtHtM6fNcHUb_MO3_T1Ec2XPG936n__WbbjZeNpsWKvGHVgryruwedjEEtwDnc0qijJEMRsvc0VZ5dkRzpM6ik01m5Ysq6vOzhkdV7NhEy_BMkqVQSed7VEnprI61btsyI66otisvnG5Dx-u5AMfwHpZlcVDYMj9nbWuSLxB7GtlEpHqvkmkibh3pgjgZbv-uW2qsVNTkC85sjICS74ClgB2usFndRGSvw_bbsGQN5Zonv9CQgDPOzHaELoY0mVRnddjVMpFwgPYqnHXvScmBw5pbwDJJUR2A6g--WVJOT1Z1ilXKfqTPHr072k9g02EZv5uPDl4DDcEZZdEIhTRNqwvZufFE7huvy2m89nTRr8YfLpqkP4EwM5rrA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Impact+of+Sarcopenia+in+Patients+with+Advanced+Prostate+Carcinoma%3A+A+Systematic+Review&rft.jtitle=Journal+of+clinical+medicine&rft.au=de+Pablos-Rodr%C3%ADguez%2C+Pedro&rft.au=Del+Pino-Sede%C3%B1o%2C+Tasmania&rft.au=Infante-Ventura%2C+Diego&rft.au=de+Armas-Castellano%2C+Aythami&rft.date=2022-12-21&rft.issn=2077-0383&rft.eissn=2077-0383&rft.volume=12&rft.issue=1&rft_id=info:doi/10.3390%2Fjcm12010057&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2077-0383&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2077-0383&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2077-0383&client=summon |